A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
Clinical trial NCT03520959 · TERMINATED
Trial details
- NCT number
- NCT03520959
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-18
- Primary completion
- 2018-11-20
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.